RecruitingPhase 3NCT06440694

Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)

Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial


Sponsor

Ottawa Hospital Research Institute

Enrollment

150 participants

Start Date

Jul 7, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Colchicine 0.5 mg po and a drug called Placebo 0.5 mg po for people with venous thromboembolism. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine 0.5 mg po

Colchicine 0.5 mg po once daily for 180 days.

DRUGPlacebo 0.5 mg po

Placebo 0.5 mg po once daily for 180 days.


Locations(4)

The Ottawa Hospital General Campus

Ottawa, Ontario, Canada

Windsor Regional Hospital

Windsor, Ontario, Canada

Centre de recherche du Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

The Sir Mortimer B. Davis Jewish General Hospital

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06440694


Related Trials